Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. monthly Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E18.59 EPS (ttm)18.21 Insider Own19.40% Shs Outstand103.08M Perf Week3.68%
Market Cap34.88B Forward P/E13.04 EPS next Y25.96 Insider Trans-0.12% Shs Float80.08M Perf Month13.02%
Income2.09B PEG2.42 EPS next Q6.85 Inst Own74.00% Short Float2.66% Perf Quarter13.99%
Sales7.62B P/S4.58 EPS this Y57.40% Inst Trans0.04% Short Ratio2.93 Perf Half Y10.97%
Book/sh96.02 P/B3.52 EPS next Y8.89% ROA16.60% Target Price386.75 Perf Year-1.08%
Cash/sh27.92 P/C12.12 EPS next 5Y7.69% ROE22.30% 52W Range271.37 - 442.00 Perf YTD-9.40%
Dividend- P/FCF17.48 EPS past 5Y40.30% ROI24.90% 52W High-20.98% Beta1.14
Dividend %- Quick Ratio3.50 Sales past 5Y26.10% Gross Margin92.20% 52W Low28.70% ATR9.28
Employees7400 Current Ratio4.00 Sales Q/Q23.10% Oper. Margin29.50% RSI (14)70.95 Volatility3.04% 2.52%
OptionableYes Debt/Eq0.07 EPS Q/Q15.80% Profit Margin28.10% Rel Volume1.67 Prev Close338.39
ShortableYes LT Debt/Eq0.07 EarningsNov 05 BMO Payout0.00% Avg Volume727.45K Price349.26
Recom2.40 SMA209.50% SMA5016.34% SMA2004.75% Volume232,767 Change3.21%
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-21-19Initiated Credit Suisse Neutral $336
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Nov-14-19 10:04AM  Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study Zacks
Nov-13-19 10:03AM  Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus Zacks
Nov-12-19 09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
08:05AM  Merck's Ebola Vaccine Gets Conditional Approval in Europe Zacks
07:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Nov-11-19 09:15AM  Celgene (CELG) Hits 52-Week High, Can the Run Continue? Zacks
08:56AM  U.S. company directors compensated more than ever, but now risk backlash Reuters
08:16AM  Have Insiders Sold Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Recently? Simply Wall St.
Nov-08-19 09:13PM  CORRECTED-INSIGHT-US company directors compensated more than ever, but now risk backlash Reuters
03:42PM  US Stocks Mixed on Friday GuruFocus.com
12:49PM  The Dow Is Down 38 Points Because Trump Hasnt Agreed to Remove Tariffs Barrons.com
10:34AM  The Zacks Analyst Blog Highlights: Alibaba, General Electric, Anthem, Progressive and Pharmaceuticals Zacks
10:18AM  Short Seller Scores Big Win as Tiny Biotech Stock Sinks 72% Bloomberg
08:24AM  Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out Barrons.com
Nov-07-19 03:03PM  Top Stock Reports for Alibaba, General Electric & Anthem Zacks
Nov-06-19 09:00AM  Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting PR Newswire
07:00AM  Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer PR Newswire
Nov-05-19 04:05PM  This Big Biotech Just Crushed Earnings Views, Unveiled $1 Billion Buyback Investor's Business Daily +6.93%
12:43PM  The Dow Is Up 23 Points as Trade-Deal Hopes Waver Barrons.com
11:56AM  Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength Zacks
07:55AM  Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates Zacks
06:58AM  UPDATE 3-Eylea powers Regeneron's third-quarter profit beat; shares rise Reuters
06:40AM  Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer PR Newswire
06:39AM  Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent Reuters
06:30AM  Regeneron Reports Third Quarter 2019 Financial and Operating Results PR Newswire
01:38AM  Regeneron Pharma Earnings, Revenue Beat in Q3 Investing.com
Nov-04-19 11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
09:58AM  Why Regeneron (REGN) Might Surprise This Earnings Season Zacks
Nov-01-19 11:05AM  Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? Zacks
10:34AM  Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates Zacks
Oct-31-19 12:20PM  Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%? Simply Wall St.
11:34AM  Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales Zacks
Oct-30-19 10:56AM  Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More Zacks
10:34AM  Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y Zacks
Oct-29-19 10:32AM  Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
08:15AM  Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire
Oct-28-19 05:10PM  11 Stocks With The Highest Gross Margins Benzinga
11:33AM  Sanofi (SNY) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 11:25AM  Amgen (AMGN) to Report Q3 Earnings: What's in the Cards? Zacks
09:51AM  Biotech Fund Investors Are Fleeing, but Biogen Stock and Others Are Rising Barrons.com
07:05AM  Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For PR Newswire
07:00AM  Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good PR Newswire
Oct-24-19 04:08PM  Amgen Cuts The Price Of A Key Drug Prodding A Rival Biotech To Slide Investor's Business Daily
Oct-23-19 10:53AM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
Oct-22-19 10:51AM  Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y Zacks
Oct-18-19 08:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Oct-14-19 11:46AM  3 Undervalued Stocks to Buy According to Goldman Sachs InvestorPlace
Oct-11-19 04:27PM  Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off Investor's Business Daily
Oct-10-19 06:22PM  Hedge Funds Have Never Been This Bullish On Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
10:11AM  Wet AMD Space in Focus: New Drug Approvals & Key Advancements Zacks
09:57AM  Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study Zacks
09:30AM  Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019 PR Newswire
Oct-09-19 12:07PM  New Novartis Drug Tabbed as Blockbuster GuruFocus.com
11:10AM  Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval Zacks
Oct-08-19 04:10PM  Can This Pharma Giant Undercut Regeneron's Biggest Moneymaker? Investor's Business Daily
Oct-03-19 03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
Oct-01-19 10:23AM  Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Excessively Paying Its CEO? Simply Wall St.
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
10:46AM  Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study Zacks
Sep-29-19 09:15PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 27 GuruFocus.com
Sep-26-19 11:59AM  Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late Zacks
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 04:19PM  Why Investors Are Beginning To Doubt This Biotech's R&D Prowess Investor's Business Daily
Sep-23-19 12:08PM  Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent Zacks
11:13AM  The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron Zacks
10:54AM  Sanofi and Regeneron Stocks Will Gain Because Dupixent Collaboration is Big, Analysts Say Barrons.com
Sep-20-19 02:14PM  Top Research Reports for Target, Illumina & T-Mobile US Zacks
07:50AM  Regeneron Rises After European Committee Adopts Positive Opinion on Dupixent TheStreet.com
06:59AM  The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) PR Newswire
06:44AM  CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire
Sep-19-19 11:02AM  Alnylam Focuses on Pipeline Development Amid Competition Zacks
Sep-18-19 06:59AM  Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis PR Newswire
Sep-17-19 10:27AM  Alnylam Begins Phase III Study on Onpattro for New Indication Zacks
07:00AM  Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies PR Newswire
Sep-16-19 01:18PM  Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Zacks
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-13-19 10:08AM  Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Zacks
10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-11-19 06:01AM  Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe Zacks
Sep-08-19 05:09PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 6 GuruFocus.com
Sep-05-19 09:31AM  Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound? Zacks
Sep-04-19 10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
Aug-30-19 10:26AM  Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study Zacks
06:30AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
Aug-29-19 09:16AM  Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court Zacks
07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga
Aug-28-19 04:56PM  U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 PR Newswire
04:18PM  U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
03:41PM  UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
03:18PM  U.S. judge rules for Sanofi in Amgen patent fight Reuters
10:43AM  Amgen Faces Trouble in the Anti-Cholesterol-Drug Battle, Analyst Says Barrons.com
Aug-27-19 06:00AM  The region's largest construction project is taking shape on Regeneron's campus American City Business Journals
Aug-26-19 04:49PM  Inovio (INO) Down More Than 30% in 3 Months: Here's Why Zacks
11:05AM  Esperion's Drugs in Review Hold Potential, Funds a Concern Zacks
09:49AM  Read This Before You Buy Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Because Of Its P/E Ratio Simply Wall St.
Aug-22-19 01:26PM  Bill Nygren Drills Into Permian Basin Oil GuruFocus.com
11:55AM  The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron Zacks
Aug-21-19 12:05PM  The Zacks Analyst Blog Highlights: Estee Lauder, Becton, Dickinson, Applied Materials, Regeneron and HollyFrontier Zacks
11:00AM  Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More Zacks
Aug-20-19 05:14PM  Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorNov 12Option Exercise273.674,5001,231,5154,823Nov 13 04:11 PM
BROWN MICHAEL SDirectorNov 12Sale349.004,5001,570,500323Nov 13 04:11 PM
GOLDSTEIN JOSEPH LDirectorNov 08Sale340.441,000340,44010,323Nov 08 05:02 PM
STAHL NEILEVP Research and DevelopmentNov 08Sale338.527,3642,492,88822,455Nov 12 04:05 PM
VAGELOS P ROYChairman of the BoardMay 24Option Exercise21.25153,7923,268,080468,669May 29 04:16 PM
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM